Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 26 of 144 for:    Open Studies | NIA

Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified March 2017 by University of Texas at Austin
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
University of Texas at Austin
ClinicalTrials.gov Identifier:
NCT03082755
First received: March 6, 2017
Last updated: March 10, 2017
Last verified: March 2017
  Purpose
Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation. The investigators propose a clinical trial to better elucidate whether a sleep disorder, restless legs syndrome, may be a mechanism for nighttime agitation, and if treatment with gabapentin enacarbil (Horizant®) reduces nighttime agitation, improves sleep, reduces restless legs syndrome behaviors, and reduces antipsychotic medications.

Condition Intervention Phase
Alzheimer Disease
Drug: Gabapentin Enacarbil
Drug: Placebo Oral Tablet
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
The investigators plan to conduct a pilot, 8-week, double-blind, placebo-controlled randomized clinical trial of GEn versus placebo, in 136 nursing home residents with nighttime agitation, RLS, and moderate to severe Alzheimer's Disease. A placebo arm will allow for a thorough and systematic assessment of the safety of GEn in this specific patient population. A 2-month post-trial follow-up will assess whether RLS treatment is continued by providers and antipsychotics are reduced.
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Masking Description:
The pharmacy, 40 Acres Pharmacy, will maintain records of group assignment. Sealed envelopes with each participant's assignment for a specific home will also be kept in a secure and locked location in each home that can be accessed only by the registered nurse in charge on each shift. The envelopes will be available in each home in the event that unmasking of assignment is needed during hours when 40 Acres Pharmacy is closed (nights, weekends, holidays). These sealed envelopes may be opened only by physician's order. Participants, their legally authorized representatives and families, participants' physicians, nursing home staff, investigators, and all study personnel will be masked to group assignment. Emergency unmasking of group assignment is expected to be rare. The DSMB will develop guidelines for emergency unmasking.
Primary Purpose: Treatment
Official Title: Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by University of Texas at Austin:

Primary Outcome Measures:
  • Nighttime Agitation - Cohen Mansfield Agitation Inventory (CMAI) - Direct Observation [ Time Frame: Change from baseline at 8 weeks ]
    The CMAI, modified for direct nighttime observation, will be used to collect objective data on nighttime agitation. Research Assistants (RAs) continuously observe the persons with dementia and record agitation behaviors every 5 minutes. The measure requires that the RAs first note whether the participant is behaviorally awake or asleep. Sleep is defined as a quiet state with eyes closed. Nighttime agitation behaviors are scored during wake. The RA will directly observe the participant when he, or she, is out of bed and record the observations using the CMAI. After the participant has gone to bed, the RA will observe him, or her, via a video camera placed in the bedroom and a small handheld monitor located in a hallway or room adjacent to the bedroom. The monitor will be shielded from view of non-research personnel when on, and turned off between 5-minute observations. The RAs will endeavor to be as sensitive as possible to the privacy of participants.


Secondary Outcome Measures:
  • Nighttime Agitation - Cohen Mansfield Agitation Inventory (CMAI) - Caregiver Version. [ Time Frame: Change from baseline at 8 weeks ]
    The same primary caregivers, if possible, on the evening and night shifts will each complete the CMAI Caregiver Version at baseline and 8 weeks.

  • Nighttime Agitation - Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC). [ Time Frame: Change from baseline at 8 weeks ]
    The mADCS-CGIC measures clinically meaningful change in the patient's condition relative to baseline on a 7-point Likert scale (markedly worse to markedly improved). The scale was modified to assess items specific to agitation, producing a global rating of change in agitation. This scale will be completed by the study Advanced Practice Nurse (APN) based on physical examination and interviews with nursing home caregivers and persons with dementia (if able).

  • Sleep Disturbance - Direct Observation [ Time Frame: Change from baseline at 8 weeks ]
    The RA will continuously observe the participant in the evening and night and note every 5 minutes whether the participant is behaviorally awake or asleep. The sleep disturbance outcome will be collected at baseline and 8 weeks. Sleep and wake will be defined as percent of observations asleep or awake on Night 1, 5 pm-10 pm; Night 2,10 pm-3 am; and Night 3, 3 am-8 am. The investigators have chosen to observe on 3 nights at different times to capture any night-to-night and time of night variability in sleep.

  • Sleep Disturbance - Behavioral Indicators Test - Restless Legs (BIT-RL) [ Time Frame: Change from baseline at 8 weeks ]
    The BIT-RL consists of two parts: 1) Behavioral Indicators - direct observations for RLS behaviors, such as kicking or rubbing legs (8 items), and 2) Clinical Indicators - medical history or family informant interview (3 items), interviews with caregivers (2 items), and an interview with the resident with dementia (1 item). The research assistants (RAs) will continuously observe each participant for RLS behaviors for 20 minutes on one evening, between 6 pm and the usual bedtime. The study APN will assess for the Restless Legs Syndrome Clinical Indicators by reviewing the medical records, and interviewing family members, evening and night shift nurses, and participants. One item, leg discomfort (yes or no) requires an answer from the participant with dementia. The APN will assess for discomfort in legs in the evening during the interval when the evening nurses report that the participant with dementia is most restless.

  • Sleep Disturbance - Micro-Mini Motionlogger® Actigraph [ Time Frame: Change from baseline at 8 weeks ]
    The micro-mini actigraph is wristwatch-sized accelerometer worn on the wrist. In the investigators' previous studies with over 400 nursing home residents with dementia the investigators have "locked" the actigraph on the participant's wrist with a plastic tie that is comfortable to wear, yet difficult to remove. The actigraph is waterproof and can be left on during showers. Nighttime total sleep time is the main actigraphy sleep outcome. The investigators also will measure other sleep disturbance variables, including nighttime wake after sleep onset, sleep efficiency, sleep latency, and awakenings with the actigraph. Daytime will be defined as 6 am-10 pm, and nighttime will be defined as 10 pm- 6 am. Because the investigators have found that sleep varies in persons with dementia and multiple nights are often needed to obtain a more reliable measure, the investigators will measure sleep for 5 days and nights at baseline and 5 days and nights at 8 weeks.


Other Outcome Measures:
  • Safety - Adverse Event Checklist [ Time Frame: Baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8 ]
    The checklist consists of adverse events reported in greater than 1% of participants in previous studies on GEn, falls, and an "other" write in category. Since persons with dementia may not be able to verbally report adverse events, the APN will use physical examination and review of systems, visual observation by study staff, physiological assessment, validated scoring tools, and verbal reports from caregivers, study staff, family members or participants (if able). The APN will assess suicide risk by questioning nursing home staff and family members about observed suicidal behaviors or expressed intent, and asking participants (if able). Reported adverse events will be evaluated with standard classifications: severity, outcome, and likelihood it was related to the study drug. Safety assessments will determine if an adverse event is serious or non-serious, intensity, duration, episodic nature, and outcome of the adverse event, and the relationship of the adverse event to the drug.

  • Fall Risk and Cognition - Global Rating of Fall Risk (GLORF) [ Time Frame: Baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8 ]
    This is a single question measure: "How do you judge the risk that Mr. or Mrs. X will fall within 6 months - high or low?" asked each week of a nurse or aide with personal knowledge of the resident. If possible, the same nurse or aide will complete the GLORF each week.

  • Mini-Mental State Examination (MMSE) [ Time Frame: Change from baseline at 3 weeks and at 8 weeks ]
    The MMSE (range 0-30) is a 30-item cognitive screen measuring orientation, registration, short-term memory, attention/concentration, language and constructional capacity. The MMSE is a widely used screening test of cognition and takes about 10 minutes to administer to the person with dementia.


Estimated Enrollment: 136
Anticipated Study Start Date: June 1, 2017
Estimated Study Completion Date: March 31, 2022
Estimated Primary Completion Date: March 31, 2021 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Gabapentin Enacarbil (GEn)
1 to 2 GEn tablets (300 mg) will be administered by mouth (PO) once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The study drug will be adjusted up to a maximum dosage of 600 mg as tolerated.
Drug: Gabapentin Enacarbil
1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
Other Name: Horizant
Placebo Comparator: Placebo
1 to 2 Placebo Oral Tablet(s) will be administered once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The placebo drug will be adjusted up to a maximum dosage of 2 tablets as tolerated.
Drug: Placebo Oral Tablet
1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.

Detailed Description:
Nighttime agitation and sleep disturbance in persons with dementia (PWD) causes patient suffering, may accelerate cognitive decline, leads to burdened caregivers, and is costly to manage. Pharmacological interventions are primarily antipsychotics and hypnotics. Effectiveness is unconvincing, and these drugs are associated with falls, strokes, and death. There is a lack of tailored, effective, and sustainable treatments for nighttime agitation and sleep disturbance in PWD. The investigators approach to this problem is innovative because, unlike pharmacological interventions in the past, it tailors the intervention to a treatable condition, restless legs syndrome (RLS), which may be causing the nighttime agitation and sleep disturbance. In previous research, the investigators showed that about 24% of PWD have an undiagnosed sleep disorder, RLS; that RLS was associated with nighttime agitation and sleep disturbance in PWD; and the investigators developed and validated an RLS diagnostic and outcome measure suitable for PWD. In order for the investigators' work to significantly impact standards of clinical practice, evidence is needed on whether RLS behaviors cause nighttime agitation, and if treating RLS behaviors reduces or stops nighttime agitation and improves sleep in PWD. The investigators have chosen gabapentin enacarbil (GEn), as the RLS treatment in this research because it is FDA approved for RLS and has a favorable safety profile. The investigators propose an 8-week, double-blind placebo-controlled randomized clinical trial of GEn versus placebo in 136 nursing home residents with nighttime agitation, sleep disturbance, and RLS. The specific aims of this pilot study are to: 1) Determine the effect of GEn, compared to placebo, on nighttime agitation (primary endpoint) in PWD with RLS. The investigators hypothesize that compared to the placebo control group, the treatment group will have fewer nighttime agitation behaviors. 2) Describe the safety profile of GEn compared to placebo in this population. 3) Estimate the effect size of GEn compared to placebo on nighttime sleep and RLS behaviors. The investigators hypothesize that compared to the placebo control group, the treatment group will have better nighttime sleep and fewer RLS behaviors. 4) Explore whether frequency of RLS behaviors is a causal mechanism for nighttime agitation. The investigators hypothesize that frequency of RLS behaviors will mediate the effect of GEn on nighttime agitation behaviors. The results of this study and future definitive trials have the potential to radically shift and drastically improve standards of clinical practice for assessment and treatment of three highly prevalent, often comorbid conditions in PWD: RLS, nighttime agitation, and sleep disturbance. For scientists, the results may provide insight into the mechanism for nighttime agitation and sleep disturbance in PWD and inform future research. For PWD, the findings may result in less nighttime agitation and discomfort from RLS, improved nighttime sleep, and improved sleep may enhance daytime cognitive functioning and quality of life. Application of the findings into the home setting may result in fewer nursing home admissions for PWD and less caregiver burden because the PWD (and their caregivers) can get more sleep.
  Eligibility

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged >=55 years
  • Clinical Dementia Rating (CDR) score of 2 or 3, indicating moderate to severe dementia
  • Physician diagnosis of dementia of the Alzheimer's type
  • Nighttime agitation, defined as nursing home staff report of at least a 2-week history of >= 3 nighttime agitation behaviors (e.g. general restlessness, pacing, wandering) >= 3 times a week using the Cohen Mansfield Agitation Inventory Caregiver Version and confirmed by direct observation by project staff
  • Opinion of the participant's physician that medication for agitation is appropriate
  • RLS diagnosis by study advanced practice nurse (APN) (in consult with the participant's physician, and the investigators), using the Behavioral Indicators Test-Restless Legs
  • Sleep disturbance reported by nursing home staff defined as <= 6 hours slept 10 pm-6 am and confirmed by actigraphy
  • Medically stable, defined as unchanged medications within 14 days and the absence of fever or other signs and symptoms of acute illness or delirium (e.g. urinary tract infection, pneumonia) that may cause agitation or interfere with the study protocol
  • Able to swallow medication
  • Ambulatory, with and without assistance

Exclusion Criteria:

  • Currently receiving opioids, because morphine and GEn taken together have a higher incidence of sedation and dizziness than either drug alone
  • Currently being treated for RLS
  • Diagnosis of Parkinson's disease (PD) or any other disorder causing tremor because extrapyramidal symptoms may confound RLS diagnosis and actigraphy
  • Receiving antiepileptic drugs
  • Severe psychosis
  • Alcohol consumption because combining alcohol and GEn may increase sedation and other adverse events
  • Treatment with GEn is contraindicated in the opinion of the study APN, participant's physician, or the investigators
  • Failure of past treatment with gabapentin or GEn
  • Compromised renal function as indicated by creatinine clearance <15 or on hemodialysis
  • Current participation in a clinical trial or in any study that may affect study outcomes
  • Determined to be at risk for suicide by the study APN or participant's physician
  • Any condition, that in the opinion of the study APN, participant's physician, or the investigators, makes it medically inappropriate for the patient to enroll in the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03082755

Contacts
Contact: Janet D Morrison, PhD 512 471 8061 jmorrison@mail.nur.utexas.edu

Sponsors and Collaborators
University of Texas at Austin
National Institute on Aging (NIA)
Investigators
Principal Investigator: Kathy Richards, PhD The University of Texas at Austin
Principal Investigator: Christine Kovach, PhD University of Wisconsin, Milwaukee
  More Information

Responsible Party: University of Texas at Austin
ClinicalTrials.gov Identifier: NCT03082755     History of Changes
Other Study ID Numbers: 2016-09-0152
R01AG051588-02 ( US NIH Grant/Contract Award Number )
Study First Received: March 6, 2017
Last Updated: March 10, 2017
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: Data have been prepared for sharing with other investigators. Data can be accessed at https://dataverse.tdl.org/dataset.xhtml?persistentId=doi:10.18738/T8/GDSFSQ after publication of the main study findings

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Alzheimer Disease
Restless Legs Syndrome
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Parasomnias
Gabapentin
gamma-Aminobutyric Acid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anticonvulsants
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs

ClinicalTrials.gov processed this record on April 28, 2017